{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:29:44Z","timestamp":1788820184143,"version":"build-2803163510"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ctrv.2022.102460","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T11:26:38Z","timestamp":1661599598000},"page":"102460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)\/microsatellite stable (MSS) colorectal cancer"],"prefix":"10.1016","volume":"110","author":[{"given":"Tugba","family":"Akin Telli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Bregni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Vanhooren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Saude Conde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Hendlisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sclafani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ctrv.2022.102460_b0005","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102460_b0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102460_b0015","doi-asserted-by":"crossref","first-page":"160","DOI":"10.21037\/jgo.2018.01.17","article-title":"Updates on immunotherapy for colorectal cancer","volume":"9","author":"Kalyan","year":"2018","journal-title":"J Gastrointest Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102460_b0020","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102460_b0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High\/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102460_b0030","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102460_b0035","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient\/Microsatellite Instability-High Metastatic Colorectal Cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ctrv.2022.102460_b0040","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102460_b0045","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.ctrv.2022.102460_b0050","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102460_b0055","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1002\/ijc.33115","article-title":"Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors","volume":"147","author":"Salem","year":"2020","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102460_b0060","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1053\/j.gastro.2009.12.064","article-title":"Microsatellite instability in colorectal cancer","volume":"138","author":"Boland","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2022.102460_b0065","doi-asserted-by":"crossref","unstructured":"Hegde PS, Karanikas V, Evers S. The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition.Clin Cancer Res 2016;22(8):1865-74.","DOI":"10.1158\/1078-0432.CCR-15-1507"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102460_b0070","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","article-title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"20","author":"Eng","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2022.102460_b0075","doi-asserted-by":"crossref","unstructured":"O\u2019Neil BH, Wallmark J, Lorente D, Elez E, Raimbourg J, Gomez-Roca C, et al. Pembrolizumab (MK-3475) for patients (pts) with advanced colorectal carcinoma (CRC): Preliminary results from KEYNOTE-028. Eur J Cancer 2015;51(Suppl_3):S103.","DOI":"10.1016\/S0959-8049(16)30304-5"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102460_b0080","doi-asserted-by":"crossref","first-page":"e2149040","DOI":"10.1001\/jamanetworkopen.2021.49040","article-title":"Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: a Randomized Clinical Trial","volume":"5","author":"Mettu","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102460_b0085","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jamaoncol.2020.0910","article-title":"Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the canadian cancer trials group CO.26 Study","volume":"6","author":"Chen","year":"2020","journal-title":"JAMA Oncol"},{"issue":"4_suppl","key":"10.1016\/j.ctrv.2022.102460_b0090","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.2022.40.4_suppl.008","article-title":"Nivolumab (NIVO) + 5-fluorouracil\/leucovorin\/oxaliplatin (mFOLFOX6)\/bevacizumab (BEV) versus mFOLFOX6\/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): phase 2 results from CheckMate 9X8","volume":"40","author":"Lenz","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102460_b0095","unstructured":"Grothey A. Insights Into the Mechanism of Action of Regorafenib in Colorectal Cancer. Clin Adv Hematol Oncol 2019;17(Suppl_12)(8):2-4."},{"issue":"9863","key":"10.1016\/j.ctrv.2022.102460_b0100","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102460_b0105","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102460_b0110","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s13046-021-02043-0","article-title":"Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth","volume":"40","author":"Doleschel","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2022.102460_b0115","article-title":"Molecular targeted agent and immune checkpoint inhibitor co-loaded thermosensitive hydrogel for synergistic therapy of rectal cancer","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ctrv.2022.102460_b0120","first-page":"1","article-title":"Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models","author":"Zhang","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.ctrv.2022.102460_b0125","doi-asserted-by":"crossref","first-page":"101912","DOI":"10.1016\/j.ctrv.2019.101912","article-title":"Molecular insight of regorafenib treatment for colorectal cancer","volume":"81","author":"Arai","year":"2019","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102460_b0130","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.3390\/cancers12082317","article-title":"Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: a tough challenge","volume":"12","author":"Marmorino","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2022.102460_b0135","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fcell.2018.00038","article-title":"Targeting tumor-associated macrophages as a potential strategy to enhance the response to immune checkpoint inhibitors","volume":"6","author":"Cassetta","year":"2018","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102460_b0140","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.coi.2010.01.009","article-title":"Macrophages, innate immunity and cancer: balance, tolerance, and diversity","volume":"22","author":"Mantovani","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.ctrv.2022.102460_b0145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2022.102460_b0150","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.3389\/fonc.2019.01512","article-title":"Evaluating the polarization of tumor-associated macrophages Into M1 and M2 Phenotypes in Human Cancer Tissue: technicalities and challenges in routine clinical practice","volume":"9","author":"Jayasingam","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2022.102460_b0155","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3389\/fimmu.2020.00369","article-title":"Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer","volume":"11","author":"Picard","year":"2020","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102460_b0160","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s00262-021-02861-3","article-title":"Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment","volume":"70","author":"O\u2019Brien","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102460_b0165","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102460_b0170","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","article-title":"Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy","volume":"5","author":"Cannarile","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2022.102460_b0175","doi-asserted-by":"crossref","unstructured":"Rahma OE, Hodi FS. The Intersection between Tumor Angiogenesis and Immune Suppression. Clin Cancer Res 2019;25(18):5449-57.","DOI":"10.1158\/1078-0432.CCR-18-1543"},{"key":"10.1016\/j.ctrv.2022.102460_b0180","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3389\/fimmu.2018.00978","article-title":"Targeting VEGF\/VEGFR to Modulate Antitumor Immunity","volume":"9","author":"Yang","year":"2018","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102460_b0185","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.trecan.2017.10.002","article-title":"Reprogramming tumor blood vessels for enhancing immunotherapy","volume":"3","author":"Schmittnaegel","year":"2017","journal-title":"Trends Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102460_b0190","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3390\/cancers13071724","article-title":"The Tumour Vasculature as a Target to Modulate Leucocyte Trafficking","volume":"13","author":"Zhao","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102460_b0195","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102460_b0200","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ccr.2011.02.005","article-title":"Targeting the ANG2\/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells","volume":"19","author":"Mazzieri","year":"2011","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102460_b0205","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.4049\/jimmunol.1002802","article-title":"Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion","volume":"186","author":"Coffelt","year":"2011","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102460_b0210","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccr.2011.03.016","article-title":"Multiple effects of angiopoietin-2 blockade on tumors","volume":"19","author":"Lewis","year":"2011","journal-title":"Cancer Cell"},{"issue":"385","key":"10.1016\/j.ctrv.2022.102460_b0215","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aak9670","article-title":"Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade","volume":"9","author":"Schmittnaegel","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2022.102460_b0220","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-3-030-34461-0_18","article-title":"Hypoxia compromises anti-cancer immune responses","volume":"1232","author":"Multhoff","year":"2020","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102460_b0225","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1038\/oncsis.2015.50","article-title":"Hypoxia and metabolic adaptation of cancer cells","volume":"5","author":"Eales","year":"2016","journal-title":"Oncogenes"},{"key":"10.1016\/j.ctrv.2022.102460_b0230","doi-asserted-by":"crossref","unstructured":"Wu RY, Kong PF, Xia LP, Huang Y, Li ZL, Tang YY, et al. Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma. Clin Cancer Res 2019;25(14):4530-41.","DOI":"10.1158\/1078-0432.CCR-18-2840"},{"issue":"18","key":"10.1016\/j.ctrv.2022.102460_b0235","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: an Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102460_b0240","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1016\/j.annonc.2021.05.020","article-title":"PD-2 Final result of phase IB study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer","volume":"32","author":"Kim","year":"2021","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2022.102460_b0245","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1200\/JCO.2021.39.15_suppl.3560","article-title":"Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)\/microsatellite stable (MSS) colorectal cancer (CRC)","volume":"39","author":"Fakih","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102460_b0250","doi-asserted-by":"crossref","first-page":"100383","DOI":"10.1016\/j.xcrm.2021.100383","article-title":"Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib\/II clinical trial and gut microbiome analysis","volume":"2","author":"Wang","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ctrv.2022.102460_b0255","doi-asserted-by":"crossref","unstructured":"Cousin S, Cantarel C, Guegan JP, Gomez-Roca C, Metges JP, Adenis A, et al. Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial. Clin Cancer Res 2021;27(8):2139-47.","DOI":"10.1158\/1078-0432.CCR-20-3416"},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2022.102460_b0260","doi-asserted-by":"crossref","first-page":"e15560","DOI":"10.1200\/JCO.2021.39.15_suppl.e15560","article-title":"A single-arm study on the efficacy and safety of regorafenib plus sintilimab as salvage-line treatments in non-MSI-H metastatic colorectal cancer","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.ctrv.2022.102460_b0265","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.2022.40.4_suppl.015","article-title":"Phase I\/II study of regorafenib (rego) and pembrolizumab (pembro) in refractory microsatellite stable colorectal cancer (MSSCRC)","volume":"40","author":"Barzi","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102460_b0270","article-title":"The Efficacy and Safety of Regorafenib in Combination With Anti-PD-1 Antibody in refractory microsatellite stable metastatic colorectal cancer: a retrospective study","volume":"10","author":"Li","year":"2020","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102460_b0275","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s00262-021-03083-3","article-title":"Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study","volume":"71","author":"Yang","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102460_b0280","doi-asserted-by":"crossref","first-page":"e1188","DOI":"10.1634\/theoncologist.2020-0161","article-title":"Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer","volume":"25","author":"Wang","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2022.102460_b0285","article-title":"Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer","volume":"11","author":"Sun","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102460_b0290","doi-asserted-by":"crossref","first-page":"861","DOI":"10.4149\/neo_2021_201228N1415","article-title":"Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and\/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study","volume":"68","author":"Jiang","year":"2021","journal-title":"Neoplasma"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102460_b0295","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/0284186X.2020.1871067","article-title":"Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer","volume":"60","author":"Bregni","year":"2021","journal-title":"Acta Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102460_b0300","doi-asserted-by":"crossref","first-page":"e2118416","DOI":"10.1001\/jamanetworkopen.2021.18416","article-title":"Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1\/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102460_b0305","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cncr.32522","article-title":"Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy","volume":"126","author":"Pires da Silva","year":"2020","journal-title":"Cancer"},{"issue":"36","key":"10.1016\/j.ctrv.2022.102460_b0310","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1200\/JCO.19.00709","article-title":"Lesion-level response dynamics to programmed cell death protein (PD-1) blockade","volume":"37","author":"Osorio","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102460_b0315","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102460_b0320","first-page":"122","article-title":"Immunological insights into liver metastasis associated resistance to checkpoint blockade cancer immunotherapy","volume":"200","author":"Lee","year":"2018","journal-title":"J Immunol"},{"issue":"3_suppl","key":"10.1016\/j.ctrv.2022.102460_b0325","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1200\/JCO.2021.39.3_suppl.94","article-title":"LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors\u2014Results from the colorectal cancer cohort","volume":"39","author":"Gomez-Roca","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.ctrv.2022.102460_b0330","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1200\/JCO.2022.40.4_suppl.135","article-title":"Phase II trial of cabozantinib (Cabo) plus durvalumab (Durva) in chemotherapy refractory patients with advanced mismatch repair proficient\/microsatellite stable (pMMR\/MSS) colorectal cancer (CRC): CAMILLA CRC cohort results","volume":"40","author":"Saeed","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102460_b0335","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2022.102460_b0340","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1200\/JCO.2022.40.16_suppl.3511","article-title":"Neoadjuvant nivolumab, ipilimumab, and celecoxib in MMR-proficient and MMR-deficient colon cancers: final clinical analysis of the NICHE study","volume":"40","author":"Verschoor","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222001293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222001293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:28:07Z","timestamp":1759656487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737222001293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":68,"alternative-id":["S0305737222001293"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102460","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)\/microsatellite stable (MSS) colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102460","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102460"}}